BDX:NYE-Becton Dickinson and Company (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 226.04

Change

-3.02 (-1.32)%

Market Cap

USD 35.71B

Volume

1.71M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Becton Dickinson & Co is a medical technology company, engaged in the manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, general public and clinical laboratories.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-01 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ALC Alcon AG

-0.11 (-0.12%)

USD 46.01B
RMD ResMed Inc

+0.70 (+0.31%)

USD 34.14B
BAX Baxter International Inc

-0.37 (-1.09%)

USD 18.71B
AVTR Avantor Inc

+0.49 (+3.10%)

USD 11.92B
ATR AptarGroup Inc

+1.43 (+0.96%)

USD 10.16B
TFX Teleflex Incorporated

+1.08 (+0.77%)

USD 6.39B
STVN Stevanato Group SpA

+0.09 (+0.43%)

USD 5.88B
BLCO Bausch + Lomb Corp

+0.25 (+1.77%)

USD 5.64B
WRBY Warby Parker Inc

-0.04 (-0.22%)

USD 2.55B
INFU InfuSystems Holdings Inc

-0.04 (-0.75%)

USD 0.13B

ETFs Containing BDX

UMDV:SW iShares US Medical Device.. 6.00 % 0.00 %

N/A

N/A
EQTY Kovitz Core Equity ETF 4.18 % 0.00 %

+0.24 (+-0.31%)

USD 1.19B
SPQB:XETRA Global X S&P 500® Quarte.. 3.93 % 0.00 %

-0.06 (-0.31%)

N/A
IBDK 0.00 % 0.10 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.34 (+-0.31%)

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
YLDE ClearBridge Dividend Stra.. 0.00 % 0.59 %

+0.28 (+-0.31%)

USD 0.05B
VSL 0.00 % 0.65 %

N/A

N/A
FHI:CA CI Health Care Giants Cov.. 0.00 % 0.75 %

+0.02 (+-0.31%)

CAD 0.10B
LS:CA 0.00 % 2.21 %

N/A

N/A
FHI-B:CA CI Health Care Giants Cov.. 0.00 % 0.00 %

-0.25 (-0.31%)

CAD 0.05B
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

+1.24 (+-0.31%)

USD 0.18B
EWRD:XETRA 0.00 % 0.00 %

N/A

N/A
NSGE:CA NBI Sustainable Global Eq.. 0.00 % 0.00 %

N/A

CAD 0.53B
TULV:CA TD Q U.S. Low Volatility .. 0.00 % 0.00 %

-0.02 (-0.31%)

CAD 0.07B
TACE 0.00 % 0.00 %

N/A

N/A
TEQI T. Rowe Price Equity Inco.. 0.00 % 0.00 %

+0.25 (+-0.31%)

USD 0.30B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.37% 78% C+ 54% F
Dividend Return 0.46% 60% D- 24% F
Total Return 0.09% 78% C+ 54% F
Trailing 12 Months  
Capital Gain -6.22% 72% C 29% F
Dividend Return 1.65% 78% C+ 32% F
Total Return -4.56% 67% D+ 26% F
Trailing 5 Years  
Capital Gain -0.68% 53% F 26% F
Dividend Return 7.79% 100% F 14% F
Total Return 7.11% 53% F 17% F
Average Annual (5 Year Horizon)  
Capital Gain -1.10% 48% F 27% F
Dividend Return 0.27% 48% F 23% F
Total Return 1.37% 83% B 33% F
Risk Return Profile  
Volatility (Standard Deviation) 7.16% 100% F 85% B
Risk Adjusted Return 3.74% 57% F 24% F
Market Capitalization 35.71B 100% F 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 38.20 64% 16%
Price/Book Ratio 2.62 43% 33%
Price / Cash Flow Ratio 17.15 50% 22%
Price/Free Cash Flow Ratio 17.29 54% 22%
Management Effectiveness  
Return on Equity 6.84% 69% 47%
Return on Invested Capital 4.78% 57% 47%
Return on Assets 3.70% 64% 64%
Debt to Equity Ratio 69.24% 40% 49%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector